Elicio Therapeutics Phase 2 Trial Misses Primary DFS Endpoint
Elicio Therapeutics said its Phase 2 AMPLIFY-7P study of camupepimut (ELI-002 7P) did not meet the ITT primary DFS endpoint (HR 0.85). The company cited a baseline ctDNA imbalance and plans to discuss a refined Phase 3 strategy with the FDA.